期刊文献+

左旋氨氯地平治疗轻中度高血压患者的疗效和安全性 被引量:7

Clinical effectiveness and safety of levamlodipine in treatment of patients with mild to moderate essential hypertension
下载PDF
导出
摘要 目的评价左旋氨氯地平治疗轻中度高血压患者的疗效和安全性。方法入选61例轻、中度高血压患者,随机分为试验组(苯磺酸左旋氨氯地平2.5mg/d,共8周)和对照组(氯沙坦50mg/d,共8周),按双盲、平行临床药理试验方法进行口服降压药物治疗,观察治疗前后血压、心率、空腹血糖、血清胰岛素、总胆固醇、三酰甘油、谷丙转氨酶、胆红素、肌酐等变化,按稳态模型(HOMA)计算胰岛素抵抗指数,并记录服药期间可能发生的不良事件。结果高血压患者经两药治疗后有效率均为100%,两组受试者治疗后收缩压和舒张压均显著下降,肝、肾功能及血糖均无变化。结论左旋氨氯地平能有效降低高血压患者的血压,服用安全,对胰岛素抵抗、血糖、血脂无影响。 Objective To evaluate the clinical effectiveness and safety of levamlodipine in treatment of patients with mild to moderate hypertension.Methods Sixty-one patients with mild to moderate hypertension were divided into two groups randomly:test group(levamlodipine,2.5mg/d)and control group(losartan,50mg/d).Patients took their pills for 8weeks.Blood pressure,heart rate and side effects were observed every two weeks.The levers of fasting blood glucose and insulin,cholesterol,triglyceride,aminotransferases,bilirubin,creatinine were determined before and after the treatment.Results Levamlodipine was effective in reducing systolic blood pressure from(145±12)mmHg to(123±10)mmHg(P0.05),and diastolic blood pressure from(96±7)mmHg to(81±7)mmHg(P0.05).The systolic blood pressure and diastolic blood pressure were decreased significantly in losartan group too.Two drugs didn′t affect the levers of glucose,cholesterol triglyceride either.Conclusion Levamlodipine is effective,sate and well tolerated in patients with mild to moderate hypertension without affecting lipids and glucose homeostasis.
出处 《四川医学》 CAS 2010年第5期574-576,共3页 Sichuan Medical Journal
关键词 左旋氨氯地平 高血压 治疗结果 安全性 levamlodipine hypertension outcome safety
  • 相关文献

参考文献4

二级参考文献45

  • 1[1]Haffner SM,Gonzalez C,Miettinen H,et al.A prospective analysis of the Homa model.The Mexico City diabetes study. Diabetes Care, 1996,19(10): 1138-1141.
  • 2[2]Reaven GM.Banting lecture 1988.Role of insulin resistance in human disease. Diabetes, 1988,37 (12): 1595 -1607.
  • 3[3]Sieglp KS,Kislighn SD.Pharmacology of losartan,an angiotensin Ⅱ receptor antagonist,in animal models of hypertension.J Hypertens, 1995,13(Suppl):515.
  • 4[4]Laakso M,Karjalainen L,Lempiainen KP.Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertens, 1996,28 (3):392-396.
  • 5Yang WS, Lee WJ, Funahashi T, et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res, 2002, 10:1104-1110.
  • 6Huang KC, Chen CL, Chuang LM, et al. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol Metab, 2003, 88: 4130-4134.
  • 7Shand BI, Scott RS, Elder PA, et al. Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes Obes Metab, 2003, 5:349-353.
  • 8Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol, 2003, 35: 807-825.
  • 9Rodondi N, Darioli R, Ramelet AA, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Ann Intern Med, 2002, 136:582-589.
  • 10Valle M, Gascon F, Martos R, et al. Relationship between high plasma leptin concentrations and metabolic syndrome in obese prepubertal children. Int J Obes Relat Metab Disord, 2003, 27:13-18.

共引文献10

同被引文献61

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部